12 August, 2014
ARANZ Healthcare Limited (AHL), the parent company of ARANZ Medical, is one of 23 high tech companies to receive a Research and Development (R and D) Growth Grant from Callaghan Innovation.
AHL chief executive Bruce Davey, PhD, says the Growth Grant will support the company’s significant investment in research and development. AHL’s core business involves commercializing 3D scanning applications, particularly for wound care and orthotics and prosthetics.
The grant, over three years, contributes 20 per cent public co-funding for qualifying firms’ eligible R and D expenditure and is designed to accelerate growth.
“We are pleased to be recognised for our extensive investment in R and D. This grant will support our development of advanced 3D scanning applications for human surfaces, which are the cornerstone of our market leadership in clinical practice and clinical research around the world,” he said.“We need to stay ahead of the market with advanced solutions that provide a platform for precision, reliability and ease of use in fields recognized to be in need of higher quality information.”
“The company is experiencing significant growth, and the Growth Grant will help maintain our leadership in a rapidly-evolving international healthcare market.”
